A Gene Transfer Study for Hemophilia A

Spark Therapeutics, Inc.25 enrolled

Overview

This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals with hemophilia A.

Hemophilia A is a condition in which blood is unable to clot effectively. It is caused by a mutation or deletion in the gene that is responsible for producing blood-clotting factor VIII protein. Individuals with hemophilia A suffer from repeated bleeding episodes, often into the joints, which can cause chronic joint disease and sometime results in death due to the inability of the blood to clot efficiently. This chronic joint disease can have significant physical, psychosocial, and quality-of-life effects, including financial burden. The current standard of care includes the use of factor-based therapies which are given either as prophylaxis or to treat bleeding, as well as new non-factor prophylaxis therapies.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hemophilia A

Interventions

SPK-8011GENETIC

A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males age 18 years or older * Confirmed diagnosis of hemophilia A as evidenced by their medical history with baseline FVIII activity levels \<=2% * Have received \>150 exposure days (EDs) to FVIII concentrates or cryoprecipitate * Have no prior history of allergic reaction to any FVIII product * Have no measurable inhibitor against FVIII as assessed by the central laboratory and have no prior history of inhibitors to FVIII protein and no clinical signs or symptoms of decreased response to FVIII administration * Agree to use reliable barrier contraception Exclusion Criteria: * Evidence of active hepatitis B or C * Currently on antiviral therapy for hepatitis B or C * Have significant underlying liver disease * Have serological evidence\* of HIV-1 or HIV-2 with CD4 counts ≤200/mm3 and who are on an antiretroviral drug regimen (\* participants who are HIV+ and stable with CD4 count \>200/mm3 and undetectable viral load are eligible to enroll) * Have detectable antibodies reactive with AAV-Spark200 capsid * Participated in a gene transfer trial within the last 52 weeks or in a clinical trial with an investigational product within the last 12 weeks

Locations (16)

University of California Davis - Hemostasis and Thrombosis Center

Sacramento, California, United States

University of Florida Health

Gainesville, Florida, United States

Outcomes

Primary Outcomes

Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse events (SAEs) were defined as adverse events that result in death, are life-threatening, require inpatient hospitalization or prolongation of existing hospitalization, result in persistent or significant disability or incapacity, are a congenital anomaly or birth defect, or are an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A TEAE is defined as an AE with an onset date on or following SPK-8011 administration. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame: From date of first dose to Week 52/End of Study (EOS) Visit

Number of Participants Who Received Corticosteroids for Presumed Immune Response

Time frame: Up to Week 52/EOS Visit

Peak Factor VIII (FVIII) Activity Levels Assessed by One-Stage Coagulation Assay (OSA)

Median peak FVIII activity up to Week 52

Time frame: Up to Week 52/EOS visit

Nominal FVIII Level by OSA at Week 52/EOS

Steady-state FVIII activity measured by median FVIII levels at week 52 by OSA.

Time frame: Up to Week 52/EOS Visit

Spontaneous Bleeds Annualized Bleeding Rate

Time frame: Week 5 up to Week 52/EOS Visit

Total Annualized FVIII Infusion Rate

Time frame: Week 5 up to Week 52/EOS Visit

Secondary Outcomes

Time to Achieve Peak FVIII Activity Level

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.